Skip to main content
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems
  • Log in
  • My alerts
  • My Cart

Main menu

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • COVID-19 Special Collection
    • Archive
    • Minireviews
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About AAC
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • AAC Podcast
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems

User menu

  • Log in
  • My alerts
  • My Cart

Search

  • Advanced search
Antimicrobial Agents and Chemotherapy
publisher-logosite-logo

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • COVID-19 Special Collection
    • Archive
    • Minireviews
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About AAC
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • AAC Podcast
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions

carbapenem-resistant Enterobacteriaceae

  • CRISPR-Cas9-Mediated Carbapenemase Gene and Plasmid Curing in Carbapenem-Resistant <em>Enterobacteriaceae</em>
    Mechanisms of Resistance
    CRISPR-Cas9-Mediated Carbapenemase Gene and Plasmid Curing in Carbapenem-Resistant Enterobacteriaceae

    Combating plasmid-mediated carbapenem resistance is essential to control and prevent the dissemination of carbapenem-resistant Enterobacteriaceae (CRE). Here, we conducted a proof-of-concept study to demonstrate that CRISPR-Cas9-mediated resistance gene and plasmid curing can effectively resensitize CRE to carbapenems. A novel CRISPR-Cas9-mediated plasmid-curing system (pCasCure) was developed and electrotransferred into...

    Mingju Hao, Yuzhang He, Haifang Zhang, Xiao-Ping Liao, Ya-Hong Liu, Jian Sun, Hong Du, Barry N. Kreiswirth, Liang Chen
  • Meropenem-Vaborbactam versus Ceftazidime-Avibactam for Treatment of Carbapenem-Resistant <em>Enterobacteriaceae</em> Infections
    Clinical Therapeutics
    Meropenem-Vaborbactam versus Ceftazidime-Avibactam for Treatment of Carbapenem-Resistant Enterobacteriaceae Infections

    The comparative efficacy of ceftazidime-avibactam and meropenem-vaborbactam for treatment of carbapenem-resistant Enterobacteriaceae (CRE) infections remains unknown. This was a multicenter, retrospective cohort study of adults with CRE infections who received ceftazidime-avibactam or meropenem-vaborbactam for ≥72 hours from February 2015 to October 2018. Patients with a localized urinary tract infection and repeat study drug...

    Renee Ackley, Danya Roshdy, Jacqueline Meredith, Sarah Minor, William E. Anderson, Gerald A. Capraro, Christopher Polk
  • Predominant Distribution of OXA-48-Like Carbapenemase in Fecal Colonization
    Letter to the Editor
    Predominant Distribution of OXA-48-Like Carbapenemase in Fecal Colonization
    Wen-Li Yuan, Jia-Li Xu, Lin Guo, Qiong-Fang Deng, De-Yao Deng
  • Activity of Imipenem-Relebactam and Meropenem-Vaborbactam against Carbapenem-Resistant, SME-Producing <span class="named-content genus-species" id="named-content-1">Serratia marcescens</span>
    Experimental Therapeutics
    Activity of Imipenem-Relebactam and Meropenem-Vaborbactam against Carbapenem-Resistant, SME-Producing Serratia marcescens

    The Serratia marcescens enzyme (SME) is a chromosomally encoded carbapenemase with no known optimal treatment. Various β-lactam/β-lactamase inhibitors and comparators were evaluated against 8 SME producers via broth microdilution. Four isolates were subsequently tested via time-kill analyses. All isolates were resistant to imipenem, imipenem-relebactam, and meropenem...

    M. Biagi, A. Shajee, A. Vialichka, M. Jurkovic, X. Tan, E. Wenzler
  • Estimating the Size of the U.S. Market for New Antibiotics with Activity against Carbapenem-Resistant <em>Enterobacteriaceae</em>
    Editor's Pick Clinical Therapeutics
    Estimating the Size of the U.S. Market for New Antibiotics with Activity against Carbapenem-Resistant Enterobacteriaceae

    New antibiotics with activity against carbapenem-resistant Enterobacteriaceae (CRE) improve outcomes of CRE-infected patients. However, companies developing these drugs have faced financial difficulties. Sales of ceftazidime-avibactam, meropenem-vaborbactam, and plazomicin in the United States totaled $101 million from February 2018 to January 2019. We estimate that...

    Cornelius J. Clancy, M. Hong Nguyen
  • Cost-Effectiveness of Ceftazidime-Avibactam for Treatment of Carbapenem-Resistant <em>Enterobacteriaceae</em> Bacteremia and Pneumonia
    Clinical Therapeutics
    Cost-Effectiveness of Ceftazidime-Avibactam for Treatment of Carbapenem-Resistant Enterobacteriaceae Bacteremia and Pneumonia

    Ceftazidime-avibactam (CAZ-AVI) may improve outcomes among patients with carbapenem-resistant Enterobacteriaceae (CRE) infections compared to those with conventional therapies. However, CAZ-AVI’s cost-effectiveness is unknown. We used a decision analytic model to estimate the health and economic consequences of CAZ-AVI-based therapy compared to colistin-based therapy (COL) for a hypothetical cohort of patients with CRE...

    Matthew S. Simon, Maroun M. Sfeir, David P. Calfee, Michael J. Satlin
  • Antecedent Carbapenem Exposure as a Risk Factor for Non-Carbapenemase-Producing Carbapenem-Resistant <span class="named-content genus-species" id="named-content-1">Enterobacteriaceae</span> and Carbapenemase-Producing <span class="named-content genus-species" id="named-content-2">Enterobacteriaceae</span>
    Mechanisms of Resistance
    Antecedent Carbapenem Exposure as a Risk Factor for Non-Carbapenemase-Producing Carbapenem-Resistant Enterobacteriaceae and Carbapenemase-Producing Enterobacteriaceae

    Carbapenem-resistant Enterobacteriaceae (CRE) can be mechanistically classified into carbapenemase-producing Enterobacteriaceae (CPE) and non-carbapenemase-producing carbapenem nonsusceptible Enterobacteriaceae (NCPCRE). We sought to investigate the effect of antecedent carbapenem exposure as a risk factor for NCPCRE versus CPE. Among all patients...

    Kalisvar Marimuthu, Oon Tek Ng, Benjamin Pei Zhi Cherng, Raymond Kok Choon Fong, Surinder Kaur Pada, Partha Pratim De, Say Tat Ooi, Nares Smitasin, Koh Cheng Thoon, Prabha Unny Krishnan, Michelle Lay Teng Ang, Douglas Su Gin Chan, Andrea Lay Hoon Kwa, Rama Narayana Deepak, Yu Kit Chan, Yvonne Fu Zi Chan, Xiaowei Huan, Kyaw Zaw Linn, Nancy Wen Sim Tee, Thean Yen Tan, Tse Hsien Koh, Raymond Tzer Pin Lin, Li Yang Hsu, Sharmila Sengupta, David L. Paterson, Eli Perencevich, Stephan Harbarth, Jeanette Teo, Indumathi Venkatachalam, for the CaPES Study Group
  • Activity of Imipenem-Relebactam and Comparator Agents against Genetically Characterized Isolates of Carbapenem-Resistant <span class="named-content genus-species" id="named-content-1">Enterobacteriaceae</span>
    Susceptibility
    Activity of Imipenem-Relebactam and Comparator Agents against Genetically Characterized Isolates of Carbapenem-Resistant Enterobacteriaceae

    Carbapenem-resistant Enterobacteriaceae (CRE) strains are an urgent public health threat. We evaluated the in vitro activities of 19 antimicrobial agents, including imipenem-relebactam, against (i) 106 CRE bloodstream isolates that primarily expressed Klebsiella pneumoniae carbapenemase (...

    Matthew C. Canver, Michael J. Satlin, Lars F. Westblade, Barry N. Kreiswirth, Liang Chen, Amy Robertson, Kathy Fauntleroy, Marisa La Spina, Katrina Callan, Stephen G. Jenkins
  • Synergistic Combinations and Repurposed Antibiotics Active against the Pandrug-Resistant <span class="named-content genus-species" id="named-content-1">Klebsiella pneumoniae</span> Nevada Strain
    Letter to the Editor
    Synergistic Combinations and Repurposed Antibiotics Active against the Pandrug-Resistant Klebsiella pneumoniae Nevada Strain
    Thea Brennan-Krohn, James E. Kirby
  • Free
    Meropenem-Vaborbactam as Salvage Therapy for Ceftazidime-Avibactam-Resistant <em>Klebsiella pneumoniae</em> Bacteremia and Abscess in a Liver Transplant Recipient
    Editor's Pick Challenging Clinical Case in Antimicrobial Resistance
    Meropenem-Vaborbactam as Salvage Therapy for Ceftazidime-Avibactam-Resistant Klebsiella pneumoniae Bacteremia and Abscess in a Liver Transplant Recipient

    We report a case of a 24-year-old liver transplant recipient who developed hepatic artery thrombosis and graft failure, which was complicated by subphrenic abscess and persistent Klebsiella pneumoniae carbapenemase (KPC)-producing K. pneumoniae bacteremia. Ceftazidime-avibactam treatment led to...

    Vasilios Athans, Elizabeth A. Neuner, Habiba Hassouna, Sandra S. Richter, George Keller, Mariana Castanheira, Kyle D. Brizendine, Amy J. Mathers

Pages

  • Next
  • 1
  • 2
  • 3
  • 4
Back to top

About

  • About AAC
  • Editor in Chief
  • Editorial Board
  • Policies
  • For Reviewers
  • For the Media
  • For Librarians
  • For Advertisers
  • Alerts
  • AAC Podcast
  • RSS
  • FAQ
  • Permissions
  • Journal Announcements

Authors

  • ASM Author Center
  • Submit a Manuscript
  • Article Types
  • Ethics
  • Contact Us

Follow #AACJournal

@ASMicrobiology

       

ASM Journals

ASM journals are the most prominent publications in the field, delivering up-to-date and authoritative coverage of both basic and clinical microbiology.

About ASM | Contact Us | Press Room

 

ASM is a member of

Scientific Society Publisher Alliance

 

American Society for Microbiology
1752 N St. NW
Washington, DC 20036
Phone: (202) 737-3600

Copyright © 2021 American Society for Microbiology | Privacy Policy | Website feedback

Print ISSN: 0066-4804; Online ISSN: 1098-6596